Alyeska Investment Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Alyeska Investment Group’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-150,000	Closed	-$1.29M	–	853
2021 Q2	$1.29M	Buy	+150,000	New	+$1.28M	0.01%	566
2018 Q3	–	Sell	-14,884	Closed	-$745K	–	541
2018 Q2	$706K	Sell	14,884 -38,595	-72%	-$2.14M	0.01%	416
2018 Q1	$3.29M	Sell	53,479 -3,192	-6%	-$168K	0.03%	319
2017 Q4	$3.05M	Sell	56,671 -35,297	-38%	-$2.1M	0.02%	297
2017 Q3	$6.2M	Sell	91,968 -7,502	-8%	-$430K	0.05%	278
2017 Q2	$5.39M	Buy	99,470 +61,380	+161%	+$2.84M	0.05%	281
2017 Q1	$1.36M	Sell	38,090 -11,910	-24%	-$408K	0.01%	420
2016 Q4	$1.6M	Buy	+50,000	New	+$1.83M	0.01%	407

Other funds holding FSTX

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group's FSTX Position: Q3 2021 in Review

Alyeska Investment Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2021, closing a stake of 150,000 shares — an estimated $1.29M sold.

Alyeska Investment Group first reported a position in FSTX in Q4 2016 and held it in 8 quarters. The position peaked at $6.2M in Q3 2017. 37 funds tracked by Wall St. Rank hold FSTX as of Q3 2021.

Alyeska Investment Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Alyeska Investment Group sold 150,000 F-star Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.29M.
Alyeska Investment Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Alyeska Investment Group's F-star Therapeutics, Inc. Common Stock position peaked at $6.2M in Q3 2017.
37 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.